Arcturus Q3 revenue $45.1M, net loss narrowed; cash runway extended to 2026; ARCT-154 on track for Japan approval

Arcturus Therapeutics Holdings Inc.

2023-Q3 EPS reported -$0.68 revenue$135,944,000

Revenue of $45.1M for Q3 2023 ($13.4M in Q3 2022); net loss $16.2M ($0.61/share) improved from $35.3M loss.
Cash, equivalents and restricted cash $369.1M; expected runway extended to end of 2026.
$35M milestone achieved from CSL Seqirus; total milestones received $365M to date.
ARCT-154 monovalent COVID vaccine on track for Japan NDA approval in December; Phase 3 bivalent trial enrollment target (850 participants) reached.
ARCT-032 Phase 1b initiated; first CF patient dosing this month; FDA Rare Pediatric Disease Designation granted.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arcturus Therapeutics Holdings Inc. reported financial results for third quarter ended Sept. 30, 2023.

Period: third quarter ended Sept. 30, 2023
Result: reported results

Exact text from the filing

On November 14, 2023, Arcturus Therapeutics Holdings Inc. (the “Company” or “Arcturus”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter ended September 30, 2023 and providing a corporate update (the “Press Release”).

View on SEC.gov

Browse all earnings releases →

Arcturus Therapeutics Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001193805-23-001493

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.